Open label evaluation of cannabidiol in dystonic movement disorders.
Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50%. Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans.
D000328:Adult; D000368:Aged; D002185:Cannabidiol / Q000009:adverse effects / Q000627:therapeutic use*; D002186:Cannabinoids / Q000627:therapeutic use*; D004421:Dystonia / Q000139:chemically induced / Q000188:drug therapy*; D004422:Dystonia Musculorum Deformans / Q000188:drug therapy; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D008297:Male; D008538:Meige Syndrome / Q000188:drug therapy; D008875:Middle Aged; D009128:Muscle Spasticity / Q000188:drug therapy; D014103:Torticollis / Q000188:drug therapy
D002186:Cannabinoids; D002185:Cannabidiol; D007980:Levodopa